Study objective-The recent availability of Haemophilus influenzae type b (HIB) conjugate vaccines prompted an examination of the costs and benefits of four and three dose HIB prevention programmes targeting all newborns in Israel. Measurements and main results-A four dose programme would reduce the number of childhood (aged 0-13) HIB cases from 184-2 to 31-3 per year, yielding a benefit ($1 03 million) to cost ($3 55 million) ratio of just 0-29Il for health services only, based on a vaccine price of$7 74 per dose. When benefits resulting from a reduction in mild handicaps and severe neurological sequelae are included, the benefit ($4-48 million) to cost ratio rises to 126/1 and it reaches 145/1 when the $0*66 million indirect benefits of reduced work absences and mortality are also included. Break even vaccine costs are $2-24 when health service benefits only are considered and $11 21 when all the benefits are included. Conclusion-In the absence of other projects with higher benefit to cost ratios, Israel should start to provide a nationwide HIB vaccination programme since the monetary benefits to society of such a programme will exceed the costs to society. A barrier to implementation may occur, however, because the costs of the programme exceed the benefits to the health services alone.
HIB prevention programmes targeting all newborns in Israel. Measurements and main results-A four dose programme would reduce the number of childhood (aged 0-13) HIB cases from 184-2 to 31-3 per year, yielding a benefit ($1 03 million) to cost ($3 55 million) ratio of just 0-29Il for health services only, based on a vaccine price of$7 74 per dose. When benefits resulting from a reduction in mild handicaps and severe neurological sequelae are included, the benefit ($4-48 million) to cost ratio rises to 126/1 and it reaches 145/1 when the $0*66 million indirect benefits of reduced work absences and mortality are also included. Break even vaccine costs are $2-24 when health service benefits only are considered and $11 21 when all the benefits are included. Conclusion-In the absence of other projects with higher benefit to cost ratios, Israel should start to provide a nationwide HIB vaccination programme since the monetary benefits to society of such a programme will exceed the costs to society. A barrier to implementation may occur, however, because the costs of the programme exceed the benefits to the health services alone. 7 Epidemiiiol Community Health 1993; 47: [485] [486] [487] [488] [489] [490] Between October 1988 and September 1990, 344 cases of Haemnophilus itifluenzae type b (HIB) infection proved by positive blood culture or spinal fluid (CSF) culture occurred in Israel (population around 5 million), 750 000 of whom were children under 5 years old. Around 61-5% of cases were male and 72-09% occurred in Jews.' Age specific incidence rates were 117, 41, 5, 2, 2 and 0 4 per 100 000 for age groups 0-1, 1-2, 2-3, 3-4, 4-5, and 5-13 years respectively. Cases in persons over 13 years old are exceedingly rare.
The case fatality rate for blood culture or CSF culture positive HIB was 2 03%.' About 53% of these HIB cases had meningitis'; the case fatality rate from HIB meningitis fell from 8-43% in 1970-79 to 3-77% in 1980-84 and to 2-96% in 1985-90.2 Around one in 588 of all children under 5 years acquires the disease and one in 1110 contracts meningitis.' HIB not only has neurological sequelae; other systemic forms such as pneumonia, sepsis, and cellulitis also occur. ' Cost-benefit studies of HIB vaccination programmes have been undertaken in the USA. These analyses, however, were based on single dose inoculation of children aged 18 or 24 months old.'2 14 To help decide whether HIB vaccinations should be provided via the public health services in Israel, this paper provides a cost-benefit analysis of a nationwide four or three dose HIB immunisation programme in which conjugate vaccine is given to children at 2, 4, 6, and 15 months, or 2, 4, and 12 months of age. Methods Demographic, epidemiological (HIB age specific incidence and transitory probabilities ofhandicaps 46Gan, AlI Ginsberg, Iniicad Kaissi'n, Ronz Dagan and severe neurological sequelae), health service (type and amount of care required for HIB cases), and economic (costs of innoculation, costs of caring for HIB cases and vaccinating contacts, labour force participation rates) data were entered into a computerised spreadsheet model.
The basic formula used is as follows:
Benefit to cost ratio=benefits of programme/costs of programme, whereCost of programnmn)ie=costs of vaccine +additional labour costs of giving innoculation +training and health education costs +transportation costs of vaccine and nurses +cold-chain costs +costs of adverse reactions.
Beniefits of prograniniiie=costs of HIB without vaccination programme -costs of HIB vaccination programme. where the costs of HIB include costs of ambulatory care, emergency room care, hospitalisation, as well as costs of prophylatic antibiotic treatments for contacts at home or in day-care situations. The costs also include costs of special education for children handicapped as a result of HIB and long term care costs for those with severe neurological sequelae.
Three different benefit to cost ratios were calculated using a discounted cash flow of 5 0% a year.
(i) The direct "health services" benefit to cost ratio, which includes only costs and benefits relating to health services (for example, costs of vaccine, ambulatory care, hospital stay, etc).
(ii) The direct "wellfare services" benefit to cost ratio, which includes only those costs and benefits relating to health services and the ministeries of education (special education costs), labour and welfare (long term care for severe neurological sequelae).
(iii) The total "social" benefit to cost ratio (that is, to society as a whole). This includes the direct welfare services costs and benefits in addition to indirect benefits related to the reductions in parental time offwork caring for their children and reductions in mortality which will be achieved by implementing the programme. The vaccine has not been shown to be associated with any serious or long term sequelae.i lx It is envisaged that the present cold-chain capacity is sufficient to handle an increased annual load of around 300 000-400 000 vaccine doses nationally (personal comunication, Dr Matas, National Public Health Laboratories). An allocation of $0 80 per targeted person per annum was estimated for additional health education and training costs'9 relating to the HIB vaccine. The health education component will be aimed at raising compliance levels through public service media broadcasts. The training component will be aimed at increasing the public health nurses ability to explain to parents and children the reasons for HIB immunization and also the nurses own awareness of the importance of following an amended immunization schedule that includes HIB. (table II) The total costs of $32 183 Total contact costs per case amount to $427, including $376 for rifampin, $32 for the 4 04 hours of nurses' time required (at $8 00 per hour), $8 for nurses' travel costs, $7 for parents and child minders for time off work and $5 for their travelling costs to the district health office. TOTAL 
Results

COSTIOF VACCINAT1ION PROGRAMMES
COSTIS OF IREATING IIB3
BENEFITS
We assumed a vaccine efficacy of 26%, 97%, lOO'Mo, and 100%/ for the four conjugate doses given at 2, 4, 6, and 15 months respectively based on trials in the USA3 and Finland.' We also assumed a compliance rate of 88% with the programme 1 and that vaccine protection would last for five years,"' 31 although it is possible that the vaccine efficacy could be even greater. We assumed there would be no reported vaccine associated cases since no increased incidence of HIB has been found during the first two weeks after immunization with HbOC. 18 32 We assumed conservatively that the true national incidence rate of HIB is IO% higher than the rates found in Dagan's study,' since for some HIB patients blood cultures were either lost, negative, or were not obtained.
The implementation of a nationwide vaccination policy, with children receiving vaccinations at average age of 2 5, 4-5, 6-5, and 15 5 months, based on estimates ofthe true age-specific incidence rates of HIB, would reduce the number of HIB cases in the cohort's lifetime from around 184 2 to 31-3 cases (table III) .
The treatment modality costs per case (table II) were then multiplied by the estimated age-specific cohort incidence of HIB (table III) , using a discount rate of 5 0%. If a four dose vaccination policy is adopted, treatment costs will fall by Gala Al Ginlsberg, Ioad Kassis, Roni Dagan Discussion A four dose programme that aims to vaccinate all children at ages 2, 4, 6, and 12 months, will reduced the incidence of HIB in an annual cohort of 100 000 persons from 184-2 to 31 3 cases (table  III) . The number of HIB cases requiring special education as a result of sequelae would fall from 24 7 to 4 2, and the number of cases requiring long term neurological care would decrease from 6 8 to 1 2 cases. Mortality associated with HIB would decrease from 3-4 to 0-58 cases in an annual cohort of newborns.
The $3 55 million costs of such a programme (at a vaccine cost of $7 74 per dose), are exceeded by the benefits from the reduction in morbidity to the welfare services ($4 48 million) or to society as a whole ($5 14 million). However, the costs of the 16 paid by federal contract in the USA,' the benefit to cost ratios to society, welfare, and the health services will rise to 2 0411, 1 76/1, and 0 43'1 respectively.
Assuming a vaccine cost of $12 38 per dose (also 50% higher than the federal contract costs in the USA) ' a three dose regimen using PRP type vaccines given at ages 2, 4, and 12 months and with vaccine efficacy of 60%S,, 89-3%S,, and I 00(0% 4 The herd immunity effect6 8 30 37 38 generated by a widespread national HIB vaccination campaign will provide external benefits to children who did not receive the HIB inoculation. The resultant efficiency of the programme over and above the expected from the vaccine efficacy assumptions of our model give us downwardly biased benefit to cost ratios.
In the absence of other projects with higher benefit to cost ratios, Israel should start to provide a nationwide vaccination programme against HIB since the monetary benefits to society of such a programme will exceed the costs to society, assuming a vaccine price of $11 21 is achieved in negotiations with the pharmaceutical companies.
A barrier to provision might occur, however, if the iMinistrv of Health were to take a narrow view of the benefits of the programme and consider only the benefits to the health services alone. The net cost to the health services alone of preventing a child and its parents suffering pain, worry, or grief as a result of contracting HIB is $16 516 
